Clinical Trials

Sponsor: ADC Therapeutics SA

Sponsor Study ID: ADCT-402-311

Study Title: A Phase 3 Randomized Study of Loncastuximab Tesirine Combined with Rituximab Versus Immunochemotherapy in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)

NCT Number: NCT04384484

Phase: III

Protocol Type: Treatment

Age Group: Adults

Disease Sites: Non-Hodgkin's Lymphoma

Study Objectives: The purpose of this study is to evaluate the efficacy of loncastuximab tesirine (ADCT-402) combined with rituximab compared to standard immunochemotherapy.



Study Documents    
(MUSC NetID required for document access)